Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 7/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766029 | 0.94 | ADORA3 (0.49) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20180112 | 0.90 | NT5E (0.60) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20180073 | 0.87 | NT5E (0.60) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20180094 | 0.86 | ADORA3 (0.53) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20167811 | 0.86 | ADORA3 (0.63) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL21766007 | 0.84 | ADORA3 (0.60) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20180038 | 0.84 | ADORA1 (0.64) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL29493240 | 0.84 | ADORA1 (0.64) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20180324 | 0.83 | ADORA1 (0.60) | NT5EADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20180115 | 0.83 | NT5E (0.59) | NT5EADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ARCUS BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ARCUS BIOSCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2018094148-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ARCUS BIOSCIENCES, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 28/4885ADORA1 29/4885 |
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 28/4885ADORA1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.